drugset
drugset / Trial / NCT04771754

The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

NCT04771754 ↗

Phase 1 Completed 16 enrolled Chelsea and Westminster NHS Foundation Trust
RandomizedCrossoverOpen-labelTreatment

Summary

This study will investigate changes in insulin resistance, lipid metabolism and endocrine profile in HIV-negative subjects exposed to dolutegravir (an antiretroviral drug used in HIV treatment) in order to investigate the role all these different factors may potentially have in weight gain recently reported in clinical cohorts.

Timeline

Start
2022-03-20
Primary completion
2023-12-31
Completion
2024-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dolutegravir Other / unclassified 50 mg Oral

Indications

No indication recorded.